The Pompe disease market is experiencing steady growth driven primarily by advancements in enzyme replacement therapies (ERT) and increasing awareness about this rare genetic disorder. Newer second-generation ERTs, such as cipaglucosidase alfa, have shown improved efficacy and patient outcomes, expanding treatment options beyond the traditional therapies.
Additionally, government...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt